Patents by Inventor Shibin Zhou
Shibin Zhou has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20170189526Abstract: Impressive responses have been observed in patients treated with checkpoint inhibitory anti-PD-1 or anti-CTLA-4 antibodies. However, immunotherapy against poorly immunogenic cancers remains a challenge. Treatment with both anti-PD-1 and anti-CTLA-4 antibodies were unable to eradicate large, modestly immunogenic CT26 tumors or metastatic 4T1 tumors. However, co-treatment with epigenetic modulating drugs and checkpoint inhibitors markedly improved treatment outcomes, curing more than 80% of them. Functional studies revealed that the primary targets of the epigenetic modulators were myeloid-derived suppressor cells (MDSCs). A PI3K-inhibitor that reduced circulating MDSCs also cured 80% of mice with metastatic 4T1 tumors when combined with immune checkpoint inhibitors. Thus, cancers resistant to immune checkpoint blockade can be cured by eliminating MDSCs.Type: ApplicationFiled: July 13, 2015Publication date: July 6, 2017Applicant: The Johns Hopkins UniversityInventors: Shibin ZHOU, Bert VOGELSTEIN, Kenneth W. KINZLER, KiBem KIM
-
Publication number: 20170020931Abstract: The presently disclosed subject matter provides methods and kits for treating solid tumors in a subject by using a combination of anti-CTLA-4 and/or anti-PD-1 antibodies with at least one member of the group consisting of a bacterium, bacterial product, and an immunoregulatory entity. In particular embodiments, the bacteria are toxin-depleted, anaerobic bacteria, such as Clostridium novyi-NT.Type: ApplicationFiled: March 31, 2015Publication date: January 26, 2017Applicant: THE JOHNS HOPKINS UNIVERSITYInventors: SHIBIN ZHOU, BERT VOGELSTEIN, KENNETH KINZLER, KIBEM KIM, SAURABH SAHA
-
Publication number: 20160051597Abstract: The present invention provides, inter alia, methods for treating or ameliorating an effect of a solid tumor present in a human. These methods include administering intratumorally to the human a unit dose of C. novyi, preferably C. novyi NT, colony forming units (CFUs), which contains about 1×103-1×107 CFUs suspended in a pharmaceutically acceptable carrier or solution. Methods for debulking a solid tumor present in a human, methods for ablating a solid tumor present in a human, a method for microscopically precise excision of tumor cells in a human, methods for treating or ameliorating an effect of a solid tumor that has metastasized to one or more sites in a human, unit doses of C. novyi, preferably C. novyi NT, CFUs, and kits for treating or ameliorating an effect of a solid tumor present in a human are also provided.Type: ApplicationFiled: March 28, 2014Publication date: February 25, 2016Inventors: Saurabh SAHA, Shibin ZHOU, Bert VOGELSTEIN, Kenneth W. KINZLER
-
Publication number: 20160045556Abstract: The present invention provides, inter alia, methods for treating or ameliorating an effect of a solid tumor present in a non-human animal. These methods include administering intratumorally to the non-human animal a unit dose of C. novyi, preferably C. novyi NT, colony forming units (CFUs), which contains about 1×106-1×1010 CFUs suspended in a pharmaceutically acceptable carrier or solution. Methods for debulking a solid tumor present in a non-human animal, a method for microscopically precise excision of tumor cells in a non-human animal, methods for treating or ameliorating an effect of a solid tumor that has metastasized to one or more sites in a non-human animal, methods for ablating a solid tumor present in a non-human animal, unit doses of C. novyi, preferably C. novyi NT, CFUs, and kits for treating or ameliorating an effect of a solid tumor present in a non-human animal are also provided.Type: ApplicationFiled: March 28, 2014Publication date: February 18, 2016Applicant: BIOMED VALLEY DISCOVERIES, INC.Inventors: Saurabh SAHA, Shibin ZHOU, Bert VOGELSTEIN, Kenneth W. KINZLER
-
Publication number: 20150306184Abstract: Clostridium novyi is an obligate anaerobe that can infect hypoxic regions within experimental tumors. We found that mice bearing large, established tumors were often cured when treated with C. novyi plus a single dose of liposomal doxorubicin. The secreted factor responsible for this phenomenon was identified and, surprisingly, proved to be a member of the lipase family. The gene encoding this protein, called liposomase, has the potential to be incorporated into diverse therapeutic methods to deliver specifically a variety of chemotherapeutic agents to tumors.Type: ApplicationFiled: December 1, 2014Publication date: October 29, 2015Inventors: Ian Cheong, Shibin Zhou, Kenneth W. Kinzler, Bert Vogelstein
-
Patent number: 8901100Abstract: Clostridium novyi is an obligate anaerobe that can infect hypoxic regions within experimental tumors. We found that mice bearing large, established tumors were often cured when treated with C. novyi plus a single dose of liposomal doxorubicin. The secreted factor responsible for this phenomenon was identified and, surprisingly, proved to be a member of the lipase family. The gene encoding this protein, called liposomase, has the potential to be incorporated into diverse therapeutic methods to deliver specifically a variety of chemotherapeutic agents to tumors.Type: GrantFiled: August 9, 2013Date of Patent: December 2, 2014Assignee: The Johns Hopkins UniversityInventors: Ian Cheong, Shibin Zhou, Kenneth W. Kinzler, Bert Vogelstein
-
Patent number: 8691186Abstract: The instant invention provides a method for diagnosing an infection in a subject by administering to the subject a compound suitable for imaging which binds to a thymidine kinase present in the infecting organism, and obtaining an image of the subject to determine the presence and location of the compound, wherein a localization of the compound is indicative that the subject has an infection.Type: GrantFiled: August 28, 2012Date of Patent: April 8, 2014Assignee: The Johns Hopkins UniversityInventors: Martin G. Pomper, Chetan Bettegowda, Catherine Foss, Shibin Zhou, Kenneth Kinzler, Bert Vogelstein
-
Publication number: 20130323167Abstract: Several agents capable of inducing vascular responses akin to those observed in inflammatory processes enhance the accumulation of nanoparticles in tumors. Exemplary vascular-active agents include a bacterium, a pro-inflammatory cytokine, and microtubule-destabilizing drugs. Such agents can increase the tumor to blood ratio of radioactivity by more than 20-fold compared to nanoparticles alone. Moreover, vascular-active agents dramatically improved the therapeutic effect of nanoparticles containing radioactive isotopes or chemotherapeutic agents.Type: ApplicationFiled: October 20, 2011Publication date: December 5, 2013Applicant: THE JOHNS HOPKINS UNIVERSITYInventors: Bert Vogelstein, Yuan Qiao, Xin Huang, Kenneth Kinzler, Shibin Zhou, Luis Diaz
-
Publication number: 20130315986Abstract: Clostridium novyi is an obligate anaerobe that can infect hypoxic regions within experimental tumors. We found that mice bearing large, established tumors were often cured when treated with C. novyi plus a single dose of liposomal doxorubicin. The secreted factor responsible for this phenomenon was identified and, surprisingly, proved to be a member of the lipase family. The gene encoding this protein, called liposomase, has the potential to be incorporated into diverse therapeutic methods to deliver specifically a variety of chemotherapeutic agents to tumors.Type: ApplicationFiled: August 9, 2013Publication date: November 28, 2013Applicant: Johns Hopkins UniversityInventors: Ian CHEONG, Shibin ZHOU, Kenneth W. KINZLER, Bert VOGELSTEIN
-
Patent number: 8568708Abstract: Clostridium novyi is an obligate anaerobe that can infect hypoxic regions within experimental tumors. We found that mice bearing large, established tumors were often cured when treated with C. novyi plus a single dose of liposomal doxorubicin. The secreted factor responsible for this phenomenon was identified and, surprisingly, proved to be a member of the lipase family. The gene encoding this protein, called liposomase, has the potential to be incorporated into diverse therapeutic methods to deliver specifically a variety of chemotherapeutic agents to tumors.Type: GrantFiled: December 3, 2012Date of Patent: October 29, 2013Assignee: The John Hopkins UniversityInventors: Ian Cheong, Shibin Zhou, Kenneth W. Kinzler, Bert Vogelstein
-
Patent number: 8444963Abstract: Clostridium novyi is an obligate anaerobe that can infect hypoxic regions within experimental tumors. We found that mice bearing large, established tumors were often cured when treated with C. novyi plus a single dose of liposomal doxorubicin. The secreted factor responsible for this phenomenon was identified and, surprisingly, proved to be a member of the lipase family. The gene encoding this protein, called liposomase, has the potential to be incorporated into diverse therapeutic methods to deliver specifically a variety of chemotherapeutic agents to tumors.Type: GrantFiled: June 19, 2007Date of Patent: May 21, 2013Assignee: John Hopkins UniversityInventors: Ian Cheong, Shibin Zhou, Kenneth W. Kinzler, Bert Vogelstein
-
Publication number: 20130064767Abstract: The instant invention provides a method for diagnosing an infection in a subject by administering to the subject a compound suitable for imaging which binds to a thymidine kinase present in the infecting organism, and obtaining an image of the subject to determine the presence and location of the compound, wherein a localization of the compound is indicative that the subject has an infection.Type: ApplicationFiled: August 28, 2012Publication date: March 14, 2013Applicant: The Johns Hopkins UniversityInventors: Martin G. Pomper, Chetan Bettegowda, Catherine Foss, Shibin Zhou, Kenneth Kinzler, Bert Vogelstein
-
Patent number: 8273326Abstract: The instant invention provides a method for diagnosing an infection in a subject by administering to the subject a compound suitable for imaging which binds to a thymidine kinase present in the infecting organism, and obtaining an image of the subject to determine the presence and location of the compound, wherein a localization of the compound is indicative that the subject has an infection.Type: GrantFiled: June 20, 2005Date of Patent: September 25, 2012Assignee: The Johns Hopkins UniversityInventors: Martin G. Pomper, Chetan Bettegowda, Catherine Foss, Shibin Zhou, Kenneth Kinzler, Bert Vogelstein
-
Publication number: 20110250258Abstract: Clostridium novyi is an obligate anaerobe that can infect hypoxic regions within experimental tumors. We found that mice bearing large, established tumors were often cured when treated with C. novyi plus a single dose of liposomal doxorubicin. The secreted factor responsible for this phenomenon was identified and, surprisingly, proved to be a member of the lipase family. The gene encoding this protein, called liposomase, has the potential to be incorporated into diverse therapeutic methods to deliver specifically a variety of chemotherapeutic agents to tumors.Type: ApplicationFiled: June 19, 2007Publication date: October 13, 2011Applicant: JOHNS HOPKINS UNIVERSITYInventors: Ian Cheong, Shibin Zhou, Kenneth W. Kinzler, Bert Vogelstein
-
Publication number: 20090010844Abstract: The instant invention provides a method for diagnosing an infection in a subject by administering to the subject a compound suitable for imaging which binds to a thymidine kinase present in the infecting organism, and obtaining an image of the subject to determine the presence and location of the compound, wherein a localization of the compound is indicative that the subject has an infection.Type: ApplicationFiled: June 20, 2005Publication date: January 8, 2009Applicant: The John Hopkins UniversityInventors: Martin G. Pomper, Chetan Bettegowda, Catherine Foss, Shibin Zhou, Kenneth Kinzler, Bert Vogelstein
-
Publication number: 20060281078Abstract: hFAST-1 is a human forkhead activin signal transducer gene. The hFAST-1 protein has the ability to bind to human Smad2 and activate an activin response element (ARE). The hFAST-1-dependent activation of ARE is dependent on endogenous Smad4 and stimulation of the TGF-? receptor. The hFAST-1 protein binds to a novel DNA motif, TGT(G/T)(T/G)ATT, which is present within the ARE. This motif is important for the activation of genes responsive to ligands of the TGF-? family. The invention includes tools for investigating the TGF-? signaling pathway and screening for compounds which modulate the action of TGF-?.Type: ApplicationFiled: February 6, 2001Publication date: December 14, 2006Inventors: Shibin Zhou, Leigh Zawel, Bert Vogelstein, Kenneth Kinzler
-
Patent number: 6225441Abstract: hFAST-1 is a human forkhead activin signal transducer gene. The hFAST-1 protein has the ability to bind to human Smad2 and activate an activin response element (ARE). The hFAST-1-dependent activation of ARE is dependent on endogenous Smad4 and stimulation of the TGF-&bgr; receptor. The hFAST-1 protein binds to a novel DNA motif, TGT(G/T)(T/G)ATT, which is present within the ARE. This motif is important for the activation of genes responsive to ligands of the TGF-&bgr; family. The invention includes tools for investigating the TGF-&bgr; signaling pathway and screening for compounds which modulate the action of TGF-&bgr;.Type: GrantFiled: March 7, 2000Date of Patent: May 1, 2001Assignee: The Johns Hopkins UniversityInventors: Shibin Zhou, Leigh Zawel, Bert Vogelstein, Kenneth W. Kinzler
-
Patent number: 6110738Abstract: hFAST-1 is a human forkhead activin signal transducer gene. The hFAST-1 protein has the ability to bind to human Smad2 and activate an activin response element (ARE). The hFAST-1-dependent activation of ARE is dependent on endogenous Smad4 and stimulation of the TGF-.beta. receptor. The hFAST-1 protein binds to a novel DNA motif, TGT(G/T)(T/G)ATT, which is present within the ARE. This motif is important for the activation of genes responsive to ligands of the TGF-.beta. family. The invention includes tools for investigating the TGF-.beta. signaling pathway and screening for compounds which modulate the action of TGF-.beta..Type: GrantFiled: July 10, 1998Date of Patent: August 29, 2000Assignee: The Johns Hopkins UniversityInventors: Shibin Zhou, Leigh Zawel, Bert Vogelstein, Kenneth W. Kinzler